Search Results
Search Results
An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line Treatment in Participants with PD-L1 High (≥50% Of Tumor Cel Expressing Pd-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer. Drug Clinical Trial